Dimer Pharmaceuticals is transforming cancer and neurodegenerative disease treatment with its innovative “Oncodegenic Approach.” This strategy leverages an epidemiological connection between these conditions, where cancer and neurodegenerative diseases show an inverse relationship. By targeting shared molecular pathways, such as MYC and p53, Dimer uncovers new therapeutic opportunities. The flagship program is a pilot of Dimer’s platform technology, focusing on MYCN-amplified pediatric tumors (Pediatric High-Risk Neural Tumors) like neuroblastoma and DIPG. Central to this program is Mycinib, a novel small-molecule therapeutic disrupting previously undruggable MYCN-driven pathways, offering hope to young patients with aggressive cancers. This pilot addresses urgent needs in pediatric oncology while validating Dimer’s scalable platform for applications in adult MYC-N-driven cancers and neurodegenerative diseases.